Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. UBS has ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

The race to develop muscle-preserving treatments alongside popular obesity drugs like Eli Lillys (NYSE:LLY) Zepbound and Novo ...

Regeneron Pharmaceuticals REGN has outperformed the market over the past 20 years by 14.22% on an annualized basis producing an average annual return of 22.54%. Currently, Regeneron Pharmaceuticals ...

Dupixent approved by FDA for bullous pemphigoid, offering a new option for adults with the rare autoimmune skin disease ...

Further expanding the indications for French pharma major Sanofi’s (Euronext: SAN) mega-blockbuster Dupixent (dupilumab), the ...

Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid  Approval based on pivotal results showing improvements in sustained disease remission and ...

Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use co ...

France's Sanofi and Tarrytown, N.Y.-based Regeneron said Friday that the FDA gave green light for Dupixent as a treatment of adult patients with bullous pemphigoid, a skin disease that mainly affects ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) received a ‘Hold’ rating from Wells Fargo, which set the company’s stock price ...

Regeneron Pharmaceuticals (NASDAQ:REGN) has reportedly declined to submit a higher bid for 23andMe (OTC:MEHCQ) after a ...